LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 ...
“AMPK is a compelling pharmaceutical target and we are encouraged by the outcome of this study. Not only does the data further demonstrate the potential for PXL770 in NASH, the positive effects on DNL ...
Globally ~40% of type 2 diabetes (T2D) patients develop diabetic kidney disease (DKD), and diabetes is the leading cause of end stage renal disease, requiring dialysis or a kidney transplant. Standard ...
Nowadays, the prevalence of sedentary lifestyles and high-caloric diets leads to an imbalance between energy intake and spending. Hence, in the last decades, we have observed a significant rise in ...
Our findings demonstrate that SOX9 overexpression alleviates hepatic lipid accumulation in MASH by activating the AMPK pathway. These results highlight SOX9 as a promising therapeutic target for ...
Recent Kallyope Inc. patents report AMP-activated protein kinase (AMPK) activators potentially useful for the treatment of allergy, cancer, depression, diabetes type 2, nutrition disorders, obesity, ...
STOCKHOLM, Nov. 2, 2017 /PRNewswire/ -- O304 reduces significantly fasting plasma glucose (FPG) in type 2 diabetics The main study results are not yet finalized. Review of the initial data showed that ...
AMP-activated protein kinase (AMPK) plays a central role in maintaining energy balance in cells, especially under energy stress. While upstream activation by the kinase LKB1 is well recognized, the ...
IL-1 family member interleukin 37 (IL-37) has broad antiinflammatory properties and functions as a natural suppressor of innate inflammation. In this study, we demonstrate that treatment with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback